Wyeth To Challenge U.K. Effexor Restrictions
This article was originally published in The Pink Sheet Daily
Executive Summary
Effective Dec. 6, U.K. labeling for Effexor contraindicates the antidepressant in patients with cardiovascular disease, recommends a baseline ECG for new patients, and restricts prescribing to specialists. Wyeth intends to file a formal appeal of the decision within two weeks.
You may also be interested in...
Wyeth Effexor Promotion Cited By U.K. Health Authorities
Medicines & Healthcare products Regulatory Agency says venlafaxine promotion was found to "openly question" recommendations for restricted use of the antidepressant in cardiovascular patients. Wyeth says it was in the process of updating promotional material to reflect new labeling when the violation occurred.
Wyeth Effexor Promotion Cited By U.K. Health Authorities
Medicines & Healthcare products Regulatory Agency says venlafaxine promotion was found to "openly question" recommendations for restricted use of the antidepressant in cardiovascular patients. Wyeth says it was in the process of updating promotional material to reflect new labeling when the violation occurred.
Wyeth Sales Growth Not Dependent On Effexor XR, CEO Essner Says
The company plans to file six NDAs over the next 24 months, including the Effexor follow-on drug DVS-233. Wyeth believes the antidepressant market will eventually "start to swing back" since the products are safe and effective "within the confines of their labeling."